Monoclonal Antibodies in Transplantation

Antibody therapies in transplantation are biologic agents - monoclonal antibodies and related polyclonal preparations - that target specific immune cells or receptors to prevent or treat rejection. They include depleting agents that remove lymphocytes, non-depleting agents that block activation receptors, and the costimulation blocker belatacept, and are used mainly for induction at the time of transplant or for treating rejection.

Definition

Antibody-based immunosuppressants are biologic agents that bind defined molecular targets on immune cells - depleting those cells, blocking activation receptors, or interrupting costimulation - to suppress the alloimmune response in transplantation.

Scope

This topic covers the antibody-based immunosuppressants used in transplantation, grouped by mechanism: depleting antibodies (such as antithymocyte globulin and alemtuzumab), non-depleting receptor-blocking antibodies (such as the interleukin-2 receptor antagonist basiliximab), the B-cell-depleting antibody rituximab, and the fusion-protein costimulation blocker belatacept. It also notes their roles in induction and in antibody-mediated rejection. Although the parent descriptor is monoclonal antibodies, the topic includes closely related polyclonal and fusion-protein biologics for completeness. It is reference material, not prescribing guidance.

Core questions

• How do depleting and non-depleting antibody therapies differ in mechanism?
• Why are antibody agents used mainly for induction or for treating rejection rather than for long-term maintenance?
• How does costimulation blockade with belatacept differ from conventional small-molecule immunosuppression?
• What role do B-cell- and antibody-directed therapies play in antibody-mediated rejection?

Key concepts

• Depleting antibodies (antithymocyte globulin, alemtuzumab)
• Interleukin-2 receptor antagonist (basiliximab)
• Costimulation blockade (belatacept)
• B-cell depletion (rituximab)
• Induction immunosuppression
• Antibody-mediated rejection

Mechanisms

Antibody agents act on defined targets rather than on broad intracellular pathways. Depleting preparations - polyclonal rabbit antithymocyte globulin and the anti-CD52 monoclonal alemtuzumab - bind lymphocyte surface antigens and cause profound, prolonged depletion of T cells (and other cells), providing intense early suppression. Non-depleting agents such as the anti-CD25 monoclonal basiliximab block the interleukin-2 receptor on activated T cells, dampening their response without depletion. Belatacept, a CTLA-4-immunoglobulin fusion protein, binds CD80/CD86 on antigen-presenting cells to block the costimulatory second signal required for full T-cell activation, offering a calcineurin-inhibitor-free maintenance option. Rituximab depletes CD20-positive B cells and is used in antibody-directed settings such as antibody-mediated rejection and desensitization.

Clinical relevance

Antibody therapies allow tailoring of induction intensity to immunologic risk and provide treatment options for cellular and antibody-mediated rejection, while costimulation blockade offers a way to avoid calcineurin-inhibitor toxicity. This entry describes the mechanisms and roles of these biologics for reference and is not a basis for selecting agents or dosing in individual patients.

History

Polyclonal antilymphocyte and antithymocyte preparations were early antibody therapies, later joined by the murine anti-CD3 monoclonal muromonab. The interleukin-2 receptor antagonist basiliximab provided a well-tolerated non-depleting induction agent, while alemtuzumab offered potent depletion. Randomized trials such as the comparison of antithymocyte globulin with basiliximab and the 3C Study of alemtuzumab-based induction clarified the relative roles of these agents, and belatacept introduced costimulation blockade as a calcineurin-sparing maintenance strategy.

Debates

Which induction antibody strategy is preferable for a given immunologic risk?

Lymphocyte-depleting agents reduce early rejection more than interleukin-2 receptor antagonists but carry greater infection and other risks, so the choice between depleting and non-depleting induction depends on the recipient's rejection risk and is not settled in general.

Seminal works

• brennan-2006
• vincenti-2016

Frequently asked questions

What is the difference between depleting and non-depleting antibody therapies?

Depleting agents (such as antithymocyte globulin and alemtuzumab) physically remove lymphocytes from the circulation, producing intense and lasting suppression, whereas non-depleting agents (such as basiliximab) block an activation receptor without destroying the cells.

How does belatacept differ from drugs like tacrolimus?

Belatacept is an injectable fusion protein that blocks the costimulatory second signal needed to fully activate T cells, allowing a calcineurin-inhibitor-free regimen, whereas tacrolimus is an oral small molecule that inhibits calcineurin inside the T cell.